US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Hemab Therapeutics Holdings, Inc.

49.16

+0.96001.99%

Post-market: 49.160.00000.00%16:10 EDT

Volume:391.76K

Turnover:19.21M

Market Cap:2.30B

PE:-27.59

High:53.00

Open:48.85

Low:46.99

Close:48.20

52wk High:55.42

52wk Low:23.00

Shares:46.71M

Float Shares:16.75M

Volume Ratio:1.63

T/O Rate:2.34%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.7820

EPS(LYR):-67.5613

ROE:-46.99%

ROA:-30.11%

PB:5.05

PE(LYR):-0.73

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Hemab Therapeutics Holdings, Inc.

Exchange:

NASDAQ

Establishment Date:

2020

Employees:

- -

Office Location:

101 Main Street,Suite 1220,Cambridge,Massachusetts,United States

Website:

http://www.hemab.com

Zip Code:

02142

Phone:

Fax:

- -

Introduction:

Hemab Therapeutics Holdings, Inc. was incorporated under Delaware law on February 12, 2026. Hemab Therapeutics is a clinical-stage biotechnology company dedicated to developing therapies that transform the treatment of blood coagulation disorders, with a mission to build a leading coagulation-focused company by discovering, developing, and commercializing innovative therapies for patients worldwide suffering from serious bleeding and thrombotic conditions, including Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its lead candidate, sutacimig (HMB-001), is a bispecific antibody currently in a Phase I/II clinical trial for prophylactic treatment of Glanzmann thrombasthenia and a Phase II clinical trial for prophylactic treatment of Factor VII deficiency.

Directors

Name

Position

Benny Sorensen

Chief Executive Officer and Director and President

Akshay Vaishnaw

Independent Director

John Maraganore

Chair of the Board and Independent Director

Laura Tadvalkar

Independent Director

Linda Bain

Independent Director

Shareholders

Name

Position

Benny Sorensen

Chief Executive Officer and Director and President

Ananthram Murthy

Chief Operating Officer

Mads Behrndt

Chief Financial Officer and General Manager

Catherine Madigan

Chief Medical Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/COAG/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"COAG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COAG\",,,,,undefined,":{"symbol":"COAG","market":"US","secType":"STK","nameCN":"Hemab Therapeutics Holdings, Inc.","latestPrice":49.16,"timestamp":1787342400000,"preClose":48.2,"halted":0,"volume":391756,"hourTrading":{"tag":"盘后","latestPrice":49.16,"preClose":49.16,"latestTime":"16:10 EDT","volume":1752,"amount":86128.32,"timestamp":1787343004648,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01991701244813265,"floatShares":16750000,"shares":46705400,"eps":-1.782,"marketStatus":"Market Closed","change":0.96,"latestTime":"08-21 16:00:00 EDT","open":48.85,"high":52.9997,"low":46.99,"amount":19212195,"amplitude":0.124683,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.782,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1777608000000,"exchange":"NASDAQ","adjPreClose":48.2,"preHourTrading":{"tag":"盘前","latestPrice":49,"preClose":48.2,"latestTime":"09:28 EDT","volume":5,"amount":245,"timestamp":1787318915364,"change":0.8,"changeRate":0.016598,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":49.16,"preClose":49.16,"latestTime":"16:10 EDT","volume":1752,"amount":86128.32,"timestamp":1787343004648,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.632870483062122},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COAG\",,,,,undefined,":{"symbol":"COAG","floatShares":16750000,"roa":"-30.11%","roe":"-46.99%","lyrEps":-67.56131,"volumeRatio":1.632870483062122,"shares":46705400,"dividePrice":0,"high":52.9997,"amplitude":0.124683,"preClose":48.2,"low":46.99,"week52Low":23.0001,"pbRate":"5.05","week52High":55.42,"institutionHeld":0,"latestPrice":49.16,"eps":-1.782,"divideRate":0,"volume":391756,"delay":0,"ttmEps":-1.782,"open":48.85,"prevYearClose":18,"prevWeekClose":54.94,"prevMonthClose":47.55,"prevQuarterClose":36.73,"fiveDayClose":54.94,"twentyDayClose":47.31,"sixtyDayClose":28.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/COAG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"COAG","fiscalQuarterEnding":"2026/06","expectedEps":-0.63,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-0.8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"COAG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"COAG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1781755200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/COAG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"COAG","date":"2026-08-21","current":-27.586981,"percent":0.342105,"low":-34.170536,"twenty":-30.064832,"median":-20.629413,"eighty":-17.903131,"high":-11.042152,"avg":-23.319513,"sd":5.854658,"marketCap":2251524039},"quantilePoints":[{"date":"2026-05-01","current":-11.042152,"twenty":-11.042152,"median":-11.042152,"eighty":-11.042152,"marketCap":705737088},{"date":"2026-05-08","current":-17.79803,"twenty":-17.79803,"median":-17.407359,"eighty":-17.286354,"marketCap":1137525503},{"date":"2026-05-15","current":-19.616555,"twenty":-19.616555,"median":-17.521449,"eighty":-17.286354,"marketCap":1253752856},{"date":"2026-05-22","current":-18.185245,"twenty":-19.409118,"median":-17.853347,"eighty":-17.293269,"marketCap":1162273533},{"date":"2026-05-29","current":-19.360717,"twenty":-19.450605,"median":-18.046954,"eighty":-17.354117,"marketCap":1237401480},{"date":"2026-06-05","current":-17.56985,"twenty":-19.450605,"median":-18.185245,"eighty":-17.491025,"marketCap":1122941843},{"date":"2026-06-12","current":-18.627775,"twenty":-19.370397,"median":-18.1403,"eighty":-17.515917,"marketCap":1190556995},{"date":"2026-06-18","current":-18.288963,"twenty":-19.294337,"median":-18.002009,"eighty":-17.444006,"marketCap":1168902469},{"date":"2026-06-26","current":-18.159648,"twenty":-19.492093,"median":-18.185245,"eighty":-17.510385,"marketCap":1294673965},{"date":"2026-07-02","current":-21.291074,"twenty":-19.764526,"median":-18.302792,"eighty":-17.540809,"marketCap":1517925825},{"date":"2026-07-10","current":-24.370091,"twenty":-20.501011,"median":-18.714206,"eighty":-17.578148,"marketCap":1737441252},{"date":"2026-07-17","current":-29.172047,"twenty":-21.688778,"median":-18.837687,"eighty":-17.609955,"marketCap":2079791907},{"date":"2026-07-24","current":-30.02369,"twenty":-24.062189,"median":-19.305401,"eighty":-17.650059,"marketCap":2140508940},{"date":"2026-07-31","current":-31.09807,"twenty":-25.689482,"median":-19.512836,"eighty":-17.666654,"marketCap":2217105812},{"date":"2026-08-07","current":-34.170536,"twenty":-29.287346,"median":-19.706444,"eighty":-17.692929,"marketCap":2436154185},{"date":"2026-08-14","current":-30.277152,"twenty":-30.021629,"median":-19.996854,"eighty":-17.818774,"marketCap":2520118712},{"date":"2026-08-21","current":-27.050208,"twenty":-30.064832,"median":-20.629413,"eighty":-17.903131,"marketCap":2251524039}],"updateTime":1787506276715},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1994300807,"yearFounded":2020,"address":"101 Main Street,Suite 1220,Cambridge,Massachusetts,United States","zipCode":"02142","officePhone":"(617) 553-3952","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.hemab.com","stockEarnings":[{"period":"1week","weight":-0.1052},{"period":"1month","weight":-0.0014},{"period":"3month","weight":0.8988},{"period":"6month","weight":1.7311},{"period":"ytd","weight":1.7311}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Hemab Therapeutics Holdings, Inc. was incorporated under Delaware law on February 12, 2026. Hemab Therapeutics is a clinical-stage biotechnology company dedicated to developing therapies that transform the treatment of blood coagulation disorders, with a mission to build a leading coagulation-focused company by discovering, developing, and commercializing innovative therapies for patients worldwide suffering from serious bleeding and thrombotic conditions, including Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its lead candidate, sutacimig (HMB-001), is a bispecific antibody currently in a Phase I/II clinical trial for prophylactic treatment of Glanzmann thrombasthenia and a Phase II clinical trial for prophylactic treatment of Factor VII deficiency.","exchange":"NASDAQ","name":"Hemab Therapeutics Holdings, Inc.","nameEN":"Hemab Therapeutics Holdings, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"COAG\",market:\"US\",,,undefined,":{"directors":[{"name":"Benny Sorensen","position":"Chief Executive Officer and Director and President"},{"name":"Akshay Vaishnaw","position":"Independent Director"},{"name":"John Maraganore","position":"Chair of the Board and Independent Director"},{"name":"Laura Tadvalkar","position":"Independent Director"},{"name":"Linda Bain","position":"Independent Director"}],"executives":[{"name":"Benny Sorensen","position":"Chief Executive Officer and Director and President"},{"name":"Ananthram Murthy","position":"Chief Operating Officer"},{"name":"Mads Behrndt","position":"Chief Financial Officer and General Manager"},{"name":"Catherine Madigan","position":"Chief Medical Officer"}]}}}